Tag: Second-line RCC options

Home / Second-line RCC options

Categories

Belzutifan is approved by USFDA for advanced renal cell carcinoma

The Food and Drug Administration granted approval for belzutifan (Welireg, Merck & Co., Inc.) on December 14, 2023, for patients with advanced renal cell carcinoma (RCC) who have previously recei...
second-line-rcc-options

We Are Online! Chat With Us!
Scan the code